Clearwater International acted as financial advisor in the sale of Denmark’s market leader in sleep and respiratory care to listed US-based ResMed (NYSE:RMD).
Founded in 1996/1997 and based in Sjaelland, Denmark, Maribo Medico is Denmark’s leading value-added distributor specialising in providing quality products, compliance and education related to the diagnosis, treatment and management of sleep disordered breathing and respiratory diseases.
Anna Reiser, President of ResMed EMAA-APAC, said: “Maribo Medico’s strong team and talented leadership, their market reputation, and their commitment to research and education for sleep and respiratory medicine have helped tens of thousands of people in Denmark who suffer from sleep-disordered breathing and chronic obstructive pulmonary disease. Maribo Medico and ResMed together will accelerate growth while improving patient quality-of-life and reducing total healthcare system costs in Denmark. This combination is part of our global goal of improving 20 million lives by 2020.”
Mette Toxværd Larsen, CEO of Maribo Medico, commented: “We are very happy to join with ResMed to help even more people who suffer from sleep-disordered breathing or chronic respiratory diseases, We’ve had a strong and fruitful partnership with ResMed for more than 15 years, and now we will leverage their global strength to improve many more lives in Denmark, building our position in respiratory care and digital, telemonitoring solutions.”